News & Events - Inventiva Pharma

News & Events

Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparcil

19 October 2020

Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH

12 October 2020

Inventiva selected to present the results of its NATIVE Phase IIb clinical trial with lanifibranor in NASH during a plenary session at The Liver Meeting Digital Experience™ 2020

Inventiva to participate at several investor conferences in October 2020

24 September 2020

H1 2020 financial results and corporate business update

16 September 2020

Inventiva to participate at several investor conferences in September 2020

9 September 2020

Inventiva announces the closing of $107.7 million initial public offering on the Nasdaq Global Market

Inventiva annonce la mise à disposition d’un prospectus dans le cadre de son offre au public d’actions ordinaires sous la formes d’ADS à l’occasion de son introduction en bourse sur le Nasdaq Global Market (only in French)

Inventiva announces trading resumption of its ordinary shares on Euronext Paris

Load More

Upcoming Investors Meetings

Upcoming Science Conferences

Questions?
Get in touch!

Inventiva
Frédéric Cren
Chief Executive Officer
info@inventivapharma.com
+33 3 80 44 75 00

Brunswick
Yannick Tetzlaff / Tristan Roquet Montegon / Aude Lepreux
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

Patti Bank
Managing Director
ICR Westwicke
Patti.Bank@westwicke.com
D 415-513-1284
San Francisco, CA
www.westwicke.com

News & Events